Clinical Trial Update: Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients. [Phase 2]

View source ↗

Summary

Phase 2 single-dose pharmacology study of DG3173 and octreotide in acromegaly completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• DG3173
• OCTREOTIDE (OCTREOTIDE ACETATE)

Snippet

Sponsor: Aspireo Pharmaceuticals Limited | Conditions: Acromegaly | Phase 2 | Status: COMPLETED | Results posted: 2018-02-15